본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Ko, Yoon Ho    (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.   ); Lee, Myung Ah    (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.   ); Hong, Yeong Seon    (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.   ); Lee, Kyung Shik    (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.   ); Park, Hyun Jin    (Department of Radiology, The Catholic University of Korea, Seoul, Korea.   ); Yoo, Ie Ryung    (Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea.   ); Kim, Yeon Sil    (Department of Radiation Oncology, The Catholic University of Korea, Seoul, Korea.   ); Kim, Young Kyoon    (Division of Pulmonology, Department of Internal Medicine, The Catholic  ); Jo, Keon Hyun   Wang, Young Pil   Lee, Kyo Young   Kang, Jin Hyoung  
  • 초록

    Background Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored in several previous trials. In this retrospective study, we compared the efficacy and safety of a weekly schedule and a 3-week schedule of docetaxel monotherapy in a second-line setting. Methods Docetaxel was administered as 75 mg/m 2 on day 1 every 3 weeks or as 37.5 mg/m 2 on day 1 and 8 every 3 weeks until disease progression or severe toxicity developed. Results From October 2003 to March 2006, a total of 37 patients received docetaxel monotherapy and 36 patients could be evaluated. A total of 135 cycles were administered and then evaluated. The median overall survival was 13.3 months (95% confidence interval: 6.3~20.3) for the weekly schedule and 10.7 months (95% confidence interval: 8.3~13.0) for the 3-week schedule ( p = 0.41). The median time to progression was 3.0 months (95% confidence interval: 1.9~4.0) and 2.8 months (95% confidence interval: 1.0~4.6), respectively ( p = 0.41). The response rate was 16.7% for the weekly schedule and 21.1% for the 3-week schedule. The major form of hematologic toxicity was grade 3-4 neutropenia (3-week: 38.9%, weekly: 9.5%). The non-hematologic toxicities were similar between the two schedules. There were no treatment-related deaths. Conclusions A docetaxel weekly schedule was very tolerable and it had comparable activity to that of the 3-week docetaxel schedule. Considering the efficacy and tolerability, a docetaxel weekly schedule can be an alternative schedule for the standard treatment of NSCLC in a second-line setting.


  • 주제어

    Carcinoma .   Non-Small-Cell Lung .   Docetaxel .   Chemotherapy.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기